Want to see IN:SMSPHARMA full AI Analyst Report?
Top Page
SMS Pharmaceuticals Limited
(SMSPHARMA)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹472.00
▲(23.95% Upside)
Action:Reiterated
Date:09/19/26
The score is primarily held back by weak cash generation and persistently negative free cash flow despite the earnings rebound. Technicals are supportive with the stock trading above major moving averages and positive MACD, while valuation is balanced by a high P/E alongside a very high dividend yield.
Positive Factors
Profit and Revenue Recovery
The return to solid profitability after the FY2023 loss, alongside continued revenue growth, indicates that the business has regained operating traction. If maintained, this recovery can strengthen reinvestment capacity and support earnings development over the next several quarters.
Negative Factors
Weak Free Cash Flow
Persistent negative free cash flow shows that reported earnings are not consistently translating into cash after operating and investment needs. This can constrain internally funded expansion, increase reliance on financing, and weaken the durability of the recent earnings recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Profit and Revenue Recovery
The return to solid profitability after the FY2023 loss, alongside continued revenue growth, indicates that the business has regained operating traction. If maintained, this recovery can strengthen reinvestment capacity and support earnings development over the next several quarters.
Read all positive factors
SMS Pharmaceuticals Limited (SMSPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹44.17B
Dividend Yield0.08%
Average Volume (3M)53.02K
Price to Earnings (P/E)41.9
Beta (1Y)1.34
Revenue Growth10.25%
EPS Growth33.78%
CountryIN
Employees1,617
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)11.24
Shares Outstanding93,652,030
10 Day Avg. Volume41,248
30 Day Avg. Volume53,018
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)4.36
Price to Sales (P/S)3.87
P/FCF Ratio-37.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMS Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of...
How the Company Makes Money
SMS Pharmaceuticals Limited primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) and pharmaceutical intermediates (bulk drugs) to customers such as pharmaceutical formulation companies and other API traders/m...
SMS Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.00B | 8.87B | 7.83B | 7.09B | 5.22B | 5.15B |
| Gross Profit | 2.39B | 1.75B | 1.45B | 2.11B | 1.29B | 1.81B |
| EBITDA | 1.80B | 1.71B | 1.45B | 1.18B | 593.89M | 1.20B |
| Net Income | 1.02B | 1.02B | 691.36M | 498.26M | -70.59M | 622.20M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 13.62B | 11.53B | 10.34B | 8.80B | 8.60B |
| Cash, Cash Equivalents and Short-Term Investments | 460.75M | 460.75M | 415.86M | 361.16M | 73.78M | 465.83M |
| Total Debt | 0.00 | 3.65B | 3.11B | 2.81B | 2.54B | 2.63B |
| Total Liabilities | -7.86B | 5.77B | 5.13B | 4.98B | 4.19B | 3.89B |
| Stockholders Equity | 7.86B | 7.86B | 6.40B | 5.36B | 4.61B | 4.70B |
Cash Flow | ||||||
| Free Cash Flow | 126.58M | -926.46M | -588.57M | -20.35M | -74.71M | 129.86M |
| Operating Cash Flow | 423.25M | 379.12M | 645.23M | 501.25M | 224.50M | 402.34M |
| Investing Cash Flow | -305.04M | -1.32B | -1.24B | -520.72M | -296.86M | -271.53M |
| Financing Cash Flow | 462.69M | 981.46M | 644.32M | 306.79M | -319.69M | -69.21M |
SMS Pharmaceuticals Limited Technical Analysis
Positive
380.80
Price Trends
396.42
Positive
392.55
Positive
376.33
Positive
Market Momentum
25.53
Negative
63.47
Neutral
71.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSPHARMA, the sentiment is Positive. The current price of 380.8 is below the 20-day moving average (MA) of 439.63, below the 50-day MA of 396.42, and above the 200-day MA of 376.33, indicating a bullish trend. The MACD of 25.53 indicates Negative momentum. The RSI at 63.47 is Neutral, neither overbought nor oversold. The STOCH value of 71.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SMSPHARMA.
SMS Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹147.37B | 28.31 | ― | 0.28% | 19.59% | 47.58% | |
65 Neutral | ₹474.18B | 41.83 | ― | 0.70% | 17.57% | 46.53% | |
63 Neutral | ₹44.17B | 41.90 | ― | 0.08% | 10.25% | 33.78% | |
57 Neutral | ₹18.07B | 31.32 | ― | 0.06% | 40.45% | 174.03% | |
56 Neutral | ₹13.64B | 54.73 | ― | 1.06% | 11.96% | -28.48% | |
56 Neutral | ₹62.13B | 46.92 | ― | ― | 51.74% | 77.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:SMSPHARMA
SMS Pharmaceuticals Limited
471.60
205.63
77.31%
IN:GLAND
Gland Pharma Ltd.
2,873.60
948.66
49.28%
IN:KOPRAN
Kopran Limited
282.25
107.37
61.39%
IN:MARKSANS
Marksans Pharma Limited
325.20
161.60
98.78%
IN:NGLFINE
NGL Fine-Chem Ltd.
2,925.50
1,448.13
98.02%
IN:SENORES
Senores Pharmaceuticals Ltd.
1,349.00
631.35
87.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.